Trial · NCT01712399
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 64
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dental caries | Gastrointestinal disorders | Mavrilimumab 100 mg | 8 | 397 | 9 |
| other | Diarrhoea | Gastrointestinal disorders | Mavrilimumab 100 mg | 15 | 397 | 15 |
| other | Bronchitis | Infections and infestations | Mavrilimumab 100 mg | 44 | 397 | 59 |
| other | Gastroenteritis | Infections and infestations | Mavrilimumab 100 mg | 11 | 397 | 14 |
| other | Influenza | Infections and infestations | Mavrilimumab 100 mg | 23 | 397 | 26 |
| other | Nasopharyngitis | Infections and infestations | Mavrilimumab 100 mg | 59 | 397 | 90 |
| other | Oral herpes | Infections and infestations | Mavrilimumab 100 mg | 11 | 397 | 13 |
| other | Pharyngitis | Infections and infestations | Mavrilimumab 100 mg | 18 | 397 | 20 |
| other | Respiratory tract infection | Infections and infestations | Mavrilimumab 100 mg | 13 | 397 | 21 |
| other | Rhinitis | Infections and infestations | Mavrilimumab 100 mg | 9 | 397 | 10 |
| other | Upper respiratory tract infection | Infections and infestations | Mavrilimumab 100 mg | 31 | 397 | 43 |
| other | Urinary tract infection | Infections and infestations | Mavrilimumab 100 mg | 35 | 397 | 53 |
| other | Viral infection | Infections and infestations | Mavrilimumab 100 mg | 8 | 397 | 10 |
| other | Fall | Injury, poisoning and procedural complications | Mavrilimumab 100 mg | 8 | 397 | 8 |
| other | Alanine aminotransferase increased | Investigations | Mavrilimumab 100 mg | 8 | 397 | 8 |
| other | Hypercholesterolaemia | Metabolism and nutrition disorders | Mavrilimumab 100 mg | 9 | 397 | 9 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Mavrilimumab 100 mg | 12 | 397 | 13 |
| other | Osteoarthritis | Musculoskeletal and connective tissue disorders | Mavrilimumab 100 mg | 12 | 397 | 13 |
| other | Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | Mavrilimumab 100 mg | 38 | 397 | 78 |
| other | Headache | Nervous system disorders | Mavrilimumab 100 mg | 17 | 397 | 35 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01712399/events